205115-25-9

Upstream product

• 776-74-9 Bromodiphenylmethane 
• 10068-07-2 methyl 3-hydroxy-5-isoxazolecarboxylate 
• 908093-98-1 diazodiphenylmethane 
• 205115-33-9 2-Benzyl-3-oxo-2,3-dihydro-isoxazole-5-carboxylic acid methyl ester 
• 205115-22-6 3-benzyloxyisoxazole-5-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Evaluation of protecting groups for 3-hydroxyisoxazoles - Short access to 3-alkoxyisoxazole-5-carbaldehydes and 3-hydroxyisoxazole-5-carbaldehyde, the putative toxic metabolite of muscimol

The regioselectivity of the 3-hydroxyisoxazole-5-ester 1 is studied with respect to O- versus N-alkylation. 3-O-Alkyl products 2 are highly favoured with benzyl, benzhydryl, and allyl bromide (≥ 91:9), in contrast to known uses of 5-alkyl-3-hydroxyisoxazoles or when methylation with diazomethane (or methyl iodide) is effected. Methoxymethylation leads to the N-substituted isoxazolinone 3e only. On reduction with DIBAH, the esters 2 afford 3-O-protected 3-hydroxyisoxazole-5-carbaldehydes 4 (75-98%). For removal of the benzyl protecting groups, three variations (HBr/HOAc, H2/ Pd/BaSO4, NBS/AIBN) were found useful with 5-ester, 5-formyl, and 5-hydroxymethyl derivatives. The free 3-hydroxy-5-carbaldehyde 9, the putative toxic metabolite of the GABA agonist muscimol, is prepared accordingly. The O-protected 3-hydroxyisoxazole-5-carbaldehydes 4 constitute versatile intermediates in various routes to analogues of CNS-active amino acids and can now be obtained in a highly efficient manner.

TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL

It is intended to provide a compound that exhibits a strong antibacterial spectrum against various bacteria including gram-negative bacteria, or a pharmaceutical composition having an antibacterial activity against carbapenem-resistant bacteria. The present invention provides a compound represented by formula (I): wherein -W- is -S(=O)- or -S(=O)2-, -T- is -CR4AR4B- or -CR5AR5B-CR6AR6B-, R4A, R4B, R5A, R5B, R6A and R6B are each independently a hydrogen atom or the like, R1 is substituted or unsubstituted heterocyclyl or the like, R2A and R2B are each independently a hydrogen atom or the like, or R2A and R2B are taken together to form substituted or unsubstituted methylidene or the like, and R3 is a hydrogen atom or the like, R11 is carboxy or the like, R7A and R7b are each independently a hydrogen atom or the like, its ester form or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

PHARMACEUTICAL COMPOSITION CONTAINING TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL

PROBLEM TO BE SOLVED: To provide a pharmaceutical composition that has antibacterial activity against carbapenem-resistant bacteria. SOLUTION: A pharmaceutical composition contains a compound represented by formula (I), its ester body or their pharmaceutically acceptable salts, or their hydrates (W is S(=O) or S(=O)2; T is CR4AR4B or CR5AR5B-CR6AR6B; R4A, R4B, R5A, R5B, R6A and R6B independently represent halogen, hydroxy, carbonyl, alkyl, cycloalkyl, aryl or the like; R1 is a carbocycle or heterocycle; R2A and R2B independently represent H, amino, hydroxy and the like, or R2A and R2B together form methylidene, hydroxyimino and the like; R3 is H, methoxy or the like). SELECTED DRAWING: None COPYRIGHT: (C)2018,JPOandINPIT